In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Summit Therapeutics (SMMT), with a price target of $2.00. The company’s shares closed last Monday at $1.62.
According to TipRanks.com, Chattopadhyay is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.8% and a 31.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.
Summit Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.46 and a one-year low of $1.10. Currently, Summit Therapeutics has an average volume of 30.18K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group.
